How is Vantrela ER formulated to be abuse deterrent?
Vantrela ER (hydrocodone bitartrate) uses Teva's proprietary abuse-deterrent technology based on a multi-layer gel-forming polymer coating that regulates drug release.
What is Vantrela ER?
Vantrela ER (hydrocodone) is an opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Vantrela ER is formulated as extended-release tablets. It is a Schedule II controlled substance with a high potential for abuse and and dependence.
How is Vantrela ER Abuse-Deterrent?
Vantrela ER is formulated with physicochemical properties intended to make the tablet more difficult to manipulate. A multi-layer gel-forming polymer coating regulates drug release.
Vantrela ER resists crushing, breaking, and dissolution using a variety of tools and solvents and still retains some extended-release properties despite manipulation.
Vantrela ER will become viscous when crushed and dissolved in liquid, making injection difficult.
The abuse-deterrent properties of Vantrela ER are expected to reduce, but not totally prevent, oral, intranasal and intravenous abuse of the drug when the tablets are manipulated.
Related Medical Questions
- Which painkiller should you use?
- Oxycodone vs Hydrocodone - How do they compare?
- Norco vs Vicodin - How do they compare?